{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:38:30Z","timestamp":1790980710239,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1939,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.jacc.2007.11.080","type":"journal-article","created":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T14:18:35Z","timestamp":1210169915000},"page":"1829-1843","source":"Crossref","is-referenced-by-count":219,"title":["The Role of Aspirin in Cardiovascular Prevention"],"prefix":"10.1016","volume":"51","author":[{"given":"Armen Yuri","family":"Gasparyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jacc.2007.11.080_bib1","first-page":"8S","article-title":"Aspirin throughout the ages: a historical review","volume":"21","author":"Levesque","year":"2000","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jacc.2007.11.080_bib2","first-page":"573","article-title":"The fight against rheumatism: from willow bark to COX-1 sparing drugs","volume":"51","author":"Vane","year":"2000","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.jacc.2007.11.080_bib3","first-page":"66","article-title":"The Italian contributions to the history of salicylates","volume":"58","author":"Marson","year":"2006","journal-title":"Reumatismo"},{"key":"10.1016\/j.jacc.2007.11.080_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0773.1997.tb02060.x","article-title":"Aspirin for the second hundred years: new uses for an old drug","volume":"81","author":"Vainio","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.jacc.2007.11.080_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1016\/j.jacc.2007.11.080_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0262-1746(87)90143-0","article-title":"Influence of anti-platelet drugs on platelet-vessel wall interactions","volume":"30","author":"Rao","year":"1987","journal-title":"Prostaglandins Leukot Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib7","first-page":"217","article-title":"Aspirin and coronary heart disease","volume":"19","author":"Koutts","year":"1990","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.jacc.2007.11.080_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1471-0528.1994.tb13110.x","article-title":"Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin","volume":"101","author":"Louden","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.jacc.2007.11.080_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1476-5381.1994.tb13063.x","article-title":"Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis","volume":"112","author":"McAuliffe","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2007.11.080_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2007.11.080_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jacc.2007.11.080_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"Meade","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib17","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2007.11.080_bib19","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib20","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/01.CIR.0000142056.69970.DB","article-title":"Terms and conditions","volume":"110","author":"Hennekens","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0021-9150(78)90162-4","article-title":"Platelet aggregation studies in coronary artery disease","volume":"31","author":"Mehta","year":"1978","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2007.11.080_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","article-title":"Narrative review: aspirin resistance and its clinical implications","volume":"142","author":"Sanderson","year":"2005","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/138161206775193064","article-title":"Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance","volume":"12","author":"Macchi","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2007.11.080_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/eurheartj\/ehi684","article-title":"Aspirin and clopidogrel resistance: an emerging clinical entity","volume":"27","author":"Wang","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.thromres.2006.08.009","article-title":"Aspirin resistance: what, why and when?","volume":"119","author":"Shantsila","year":"2007","journal-title":"Thrombosis Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2006.04.005","article-title":"Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction","volume":"119","author":"Poulsen","year":"2007","journal-title":"Thrombosis Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2007-995840","article-title":"PFA-100 system: a new method for assessment of platelet dysfunction","volume":"24","author":"Mammen","year":"1998","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib30","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/S0002-8703(98)70245-5","article-title":"Assessment of platelet function assays","volume":"135","author":"Nicholson","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/01.STR.0000162719.11058.bd","article-title":"Screening for aspirin responsiveness after transient ischemic attack and stroke","volume":"36","author":"Harrison","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2007.11.080_bib32","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2003.08.072","article-title":"Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA","volume":"92","author":"Wang","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1592\/phco.23.5.579.32206","article-title":"Aspirin dosage and thromboxane synthesis in patients with vascular disease","volume":"23","author":"Hart","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2007.11.080_bib34","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.STR.0000117097.76953.A6","article-title":"Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction","volume":"35","author":"Bruno","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2007.11.080_bib36","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.jacc.2007.02.038","article-title":"Platelet surface CD62P and CD63, mean platelet volume, and soluble\/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of \u201chealthy control subjects\u201d and \u201cdisease control subjects\u201d in sinus rhythm","volume":"49","author":"Choudhury","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1378\/chest.06-2039","article-title":"Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to P-selectin and antithrombotic therapy","volume":"131","author":"Choudhury","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2007.11.080_bib38","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjhyper.2006.03.001","article-title":"Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients","volume":"19","author":"Nadar","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacc.2007.11.080_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1055\/s-0038-1657677","article-title":"Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty","volume":"78","author":"Mueller","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MBC.0b013e328040c115","article-title":"Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR)","volume":"18","author":"Pamukcu","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2007.11.080_bib44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.2005.25.7.942","article-title":"Aspirin resistance: an evaluation of current evidence and measurement methods","volume":"25","author":"Martin","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2007.11.080_bib45","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","article-title":"Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa","volume":"110","author":"Szczeklik","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2007.11.080_bib46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1345\/aph.1E227","article-title":"Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?","volume":"39","author":"Papp","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2007.11.080_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2006.03.005","article-title":"Antithrombotic effects of aspirin based on PLA1\/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease","volume":"119","author":"Dropinski","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.STR.0000151362.65339.f9","article-title":"Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?","volume":"36","author":"Gonzalez-Conejero","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2007.11.080_bib49","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2004.10.007","article-title":"The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis","volume":"149","author":"Pamukcu","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022066305399","article-title":"Aspirin resistance and genetic polymorphisms","volume":"14","author":"Cambria-Kiely","year":"2002","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2007.11.080_bib51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(03)12560-3","article-title":"Parsing an enigma: the pharmacodynamics of aspirin resistance","volume":"361","author":"FitzGerrald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2423(06)42003-5","article-title":"Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility","volume":"42","author":"Schwartz","year":"2006","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.jacc.2007.11.080_bib53","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-959300","article-title":"Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany","volume":"132","author":"Rottlaender","year":"2007","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jacc.2007.11.080_bib55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction","volume":"95","author":"Schwartz","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib56","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","article-title":"Aspirin dose for the prevention of cardiovascular disease","volume":"297","author":"Campbell","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2007.11.080_bib57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib58","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejcts.2004.12.010","article-title":"Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting?","volume":"27","author":"Zimmermann","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2007.11.080_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin","volume":"5","author":"Guthikonda","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2007.02378.x","article-title":"Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection","volume":"5","author":"Modica","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib61","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1538-7836.2004.00836.x","article-title":"Platelet activation in type 2 diabetes mellitus","volume":"2","author":"Ferroni","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/187152506776369908","article-title":"Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy","volume":"4","author":"Anfossi","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.jacc.2007.11.080_bib63","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.2174\/1381612054367337","article-title":"Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus","volume":"11","author":"Watala","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2007.11.080_bib64","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.ATV.17.11.3230","article-title":"In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia","volume":"17","author":"Davi","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2007.11.080_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.CIR.94.1.19","article-title":"Modulation of oxidant stress in vivo in chronic cigarette smokers","volume":"94","author":"Reilly","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cardfail.2003.11.004","article-title":"Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity","volume":"10","author":"Polidori","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2007.11.080_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1042\/CS20050317","article-title":"Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support","volume":"110","author":"White","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2007.11.080_bib68","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1093\/eurheartj\/ehl305","article-title":"Platelets and heart failure","volume":"27","author":"Chung","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib69","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1538-7836.2006.01958.x","article-title":"Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients","volume":"4","author":"Ohmori","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib70","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2007.11.080_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1538-7836.2007.02498.x","article-title":"Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection","author":"Cattaneo","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1538-7836.2007.02288.x","article-title":"Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications","volume":"5","author":"Dotsenko","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib73","article-title":"Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm","volume":"4","author":"Lip","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2007.11.080_bib74","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jacc.2004.07.062","article-title":"Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes","volume":"46","author":"Masoudi","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib75","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.105.602136","article-title":"Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure","volume":"113","author":"McAlister","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2004.02.006","article-title":"The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics","volume":"10","author":"Massie","year":"2004","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2007.11.080_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1388-9842(99)00055-0","article-title":"Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs. aspirin (HELAS)","volume":"1","author":"Cokkinos","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2007.11.080_bib79","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2007.11.080_bib80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cardfail.2005.07.007","article-title":"Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design","volume":"12","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2007.11.080_bib81","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2007.11.080_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00129784-200404020-00003","article-title":"Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus","volume":"4","author":"Colwell","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2007.11.080_bib83","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jacc.2006.09.046","article-title":"Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management","volume":"49","author":"Berry","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib84","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1464-5491.2004.01328.x","article-title":"Changing aspirin use in patients with type 2 diabetes in the UKPDS","volume":"21","author":"Cull","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular disease in people with diabetes mellitus","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib86","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003495-200767070-00005","article-title":"Approaches to prevention of cardiovascular complications and events in diabetes mellitus","volume":"67","author":"Coccheri","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2007.11.080_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1160\/TH04-07-0453","article-title":"Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin","volume":"93","author":"Evangelista","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00592-005-0186-y","article-title":"Prevalence of aspirin resistance in patients with type 2 diabetes","volume":"42","author":"Fateh-Moghadam","year":"2005","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jacc.2007.11.080_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003186.pub2","article-title":"Antiplatelet agents and anticoagulants for hypertension","volume":"3","author":"Lip","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2007.11.080_bib90","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0049-3848(03)00419-5","article-title":"Effect of aspirin on constitutive nitric oxide synthase and the bioavailability of NO","volume":"110","author":"Madajka","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib91","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00002512-200623070-00002","article-title":"Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables","volume":"23","author":"Feher","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacc.2007.11.080_bib92","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib93","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.crd.0000124843.85660.ed","article-title":"Atherosclerosis and systemic lupus erythematosus","volume":"12","author":"Abusamieh","year":"2004","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jacc.2007.11.080_bib94","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/art.20853","article-title":"Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2007.11.080_bib95","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/archinte.164.22.2472","article-title":"Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction","volume":"164","author":"Fischer","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/000331979804900906","article-title":"Decreased prevalence of symptomatic atherosclerosis in arthritis patients on long-term aspirin therapy","volume":"49","author":"Sloop","year":"1998","journal-title":"Angiology"},{"key":"10.1016\/j.jacc.2007.11.080_bib97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11926-004-0009-0","article-title":"Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis","volume":"6","author":"Kurth","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jacc.2007.11.080_bib98","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1345\/aph.1E514","article-title":"Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin","volume":"39","author":"Corman","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2007.11.080_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0049-3848(02)00210-4","article-title":"Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate","volume":"107","author":"Macchi","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-3-10","article-title":"Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels","volume":"3","author":"Borna","year":"2005","journal-title":"Thromb J"},{"key":"10.1016\/j.jacc.2007.11.080_bib101","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1111\/j.1538-7836.2005.01640.x","article-title":"Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial","volume":"3","author":"Eikelboom","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib102","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib103","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib105","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2007.11.080_bib106","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib107","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2007.11.080_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib109","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib110","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial","volume":"28","author":"Wang","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib111","first-page":"117","article-title":"Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial","volume":"15","author":"Serebruany","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2007.11.080_bib112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4065\/81.4.518","article-title":"Aspirin and clopidogrel resistance","volume":"81","author":"Michos","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2007.11.080_bib113","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ahj.2007.04.014","article-title":"Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis","volume":"154","author":"Snoep","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02938373","article-title":"Contemporary use of clopidogrel in patients with coronary artery disease","volume":"9","author":"Parikh","year":"2007","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2007.11.080_bib115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2005.08.058","article-title":"Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance","volume":"47","author":"Lev","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib116","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2125.2006.02792.x","article-title":"A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans","volume":"63","author":"Jakubowski","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2007.11.080_bib117","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1527-3466.2007.00013.x","article-title":"Optimizing platelet P2Y12 inhibition for patients undergoing PCI","volume":"25","author":"Steinhubl","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl","key":"10.1016\/j.jacc.2007.11.080_bib118","first-page":"S1","article-title":"European Stroke Prevention Study 2: efficacy and safety data","volume":"151","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jacc.2007.11.080_bib119","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Halkes","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2007.11.080_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001820.pub3","article-title":"Dipyridamole for preventing stroke and other vascular events in patients with vascular disease","volume":"3","author":"De Schryver","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2007.11.080_bib121","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH06-08-0451","article-title":"Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease","volume":"96","author":"Rao","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2007.11.080_bib122","first-page":"1","article-title":"Cilostazol in the management of vascular disease","volume":"26","author":"Dalainas","year":"2007","journal-title":"Int Angiol"},{"key":"10.1016\/j.jacc.2007.11.080_bib123","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","article-title":"Coronary stent restenosis in patients treated with cilostazol","volume":"112","author":"Douglas","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003748.pub2","article-title":"Cilostazol for peripheral arterial disease","volume":"1","author":"Robless","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2007.11.080_bib125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-2007-960493","article-title":"TNF-alpha-308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin","volume":"115","author":"Krayenbuehl","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jacc.2007.11.080_bib126","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/095371032000158763","article-title":"Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin","volume":"14","author":"Chakraborty","year":"2003","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2007.11.080_bib127","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF02977780","article-title":"Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses","volume":"30","author":"Cho","year":"2007","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jacc.2007.11.080_bib128","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidz\u00e9","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2007.11.080_bib129","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.667584","article-title":"Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1","volume":"115","author":"Faraday","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2007.11.080_bib130","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.295.12.1420","article-title":"Sex differences in platelet reactivity and response to low-dose aspirin therapy","volume":"295","author":"Becker","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2007.11.080_bib131","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/14622416.8.6.577","article-title":"Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin","volume":"8","author":"Li","year":"2007","journal-title":"Pharmacogenomics"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109708005706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109708005706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T05:03:39Z","timestamp":1557551019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109708005706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":131,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0735109708005706"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2007.11.080","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}